Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBT Margin (2016 - 2025)

Collegium Pharmaceutical has reported EBT Margin over the past 10 years, most recently at 14.13% for Q4 2025.

  • Quarterly results put EBT Margin at 14.13% for Q4 2025, up 464.0% from a year ago — trailing twelve months through Dec 2025 was 11.87% (down 866.0% YoY), and the annual figure for FY2025 was 11.87%, down 374.0%.
  • EBT Margin for Q4 2025 was 14.13% at Collegium Pharmaceutical, down from 20.75% in the prior quarter.
  • Over the last five years, EBT Margin for COLL hit a ceiling of 195.7% in Q3 2024 and a floor of 435.82% in Q1 2022.
  • Median EBT Margin over the past 5 years was 12.3% (2023), compared with a mean of 7.79%.
  • Biggest five-year swings in EBT Margin: crashed -45346bps in 2022 and later soared 42369bps in 2023.
  • Collegium Pharmaceutical's EBT Margin stood at 101.43% in 2021, then skyrocketed by 94bps to 6.01% in 2022, then soared by 619bps to 31.19% in 2023, then tumbled by -70bps to 9.49% in 2024, then surged by 49bps to 14.13% in 2025.
  • The last three reported values for EBT Margin were 14.13% (Q4 2025), 20.75% (Q3 2025), and 9.06% (Q2 2025) per Business Quant data.